Articles Vol. 67 No. Số CĐ12- Bệnh viện Ung bướu Nghệ An (2026) 14/08/2026

KẾT QUẢ XẠ TRỊ KỸ THUẬT ĐIỀU BIẾN LIỀU KẾT HỢP ĐỒNG THỜI HOÁ TRỊ PHÁC ĐỒ PACLITAXEL – CARBOPLATIN BỆNH UNG THƯ THỰC QUẢN 1/3 TRÊN TẠI BỆNH VIỆN UNG BƯỚU NGHỆ AN

Nguyen Hai Hoang1,2, Nguyen Van Cong1,2, Tran Thi Anh Ngoc1, Nguyen Tien Thuong1, Pham Thi Nhung1,2
1 Nghe An Oncology Hospital.
2 Bệnh viện Ung bướu Nghệ An.
DOI: 10.52163/yhc.v67iCD12.6132
627 Views
0 Downloads
Keywords
Upper-third esophageal cancer; Intensity-modulated radiotherapy (IMRT); Concurrent chemoradiotherapy; Paclitaxel - Carboplatin; RECIST 1.1.
Abstract

Objective: To evaluate the outcomes of intensity-modulated radiotherapy (IMRT) combined with concurrent Paclitaxel - Carboplatin (PC) chemotherapy in patients with upper-third esophageal cancer (EC) at Nghe An Oncology Hospital.

Subjects and Methods: A retrospective and prospective descriptive study was conducted on 32 patients with stage II-IVa upper-third esophageal cancer treated with IMRT and Paclitaxel - Carboplatin chemotherapy from January 2022 to June 2026. Post-treatment response was evaluated based on the RECIST 1.1 criteria. Early toxicities and adverse effects were assessed using the CTCAE v5.0 criteria.

Results: Dysphagia symptoms improved in 78.1% of the patients. The treatment responses were as follows: complete response (CR) in 18.8%, partial response (PR) in 59.4%, stable disease (SD) in 12.5%, and progressive disease (PD) in 9.4%. There were statistically significant differences in response rates according to T stage, and overall disease stage (p < 0.05). Early adverse effects were predominantly Grade 1-2, including dermatitis (59.4%), esophagitis (84.4%), decreased hemoglobin (18.8%), and neutropenia (15.6%).

Conclusion: The IMRT technique combined with the Paclitaxel - Carboplatin regimen for patients with upper-third esophageal cancer demonstrates high clinical and subclinical responses, with low and manageable adverse effects.

References
[1]
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers. Version 2.2025. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2025. Google Scholar
[2]
Van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074-2084. doi:10.1056/NEJMoa1112088. (CROSS trial) Google Scholar
[3]
Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090-1098. Google Scholar
[4]
Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, et al. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. J Clin Oncol. 2018;36(27):2796-2803. doi:10.1200/JCO.2018.79.1483. Google Scholar
[5]
Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, et al. Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial. JAMA Surg. 2021;156(8):721-729. Google Scholar
[6]
RTOG 85-01 Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326(24):1593-1598. Google Scholar
[7]
ARTDECO trial Hulshof MCCM, Geijsen ED, Rozema T, Oppedijk V, Buijsen J, Neelis KJ, et al. Randomized study on dose escalation in definitive chemoradiation for esophageal cancer (ARTDECO). Lancet Oncol. 2021;22(7):919-927. Google Scholar